Tarrytown-based Regeneron Pharmaceuticals, Inc. has been named the successful bidder in the bankruptcy auction for substantially all of the assets of ...

The move raises privacy concerns as the drugmaker takes control of the genetic data of millions of clients of the ...

It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly ...

The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm ...

Berlin: Bayer has received approval from the Center for Drug Evaluation (CDE) of China's National Medical Products ...

The fall of 23andMe raises privacy concerns as Regeneron buys its genetic database for $256M after bankruptcy.

In this week’s edition of InnovationRx, we look at the FDA's new rules on Covid-19 vaccines, Novartis’s acquisition strategy, ...

Regeneron: Sure. No. Great question. So we believe nothing else exists like it on the planet. We’ve invested more than anybody else in terms of building a sequence based big data set.

Regeneron Pharmaceuticals ... inking an R&D alliance with GSK in 2018 and then later building its own pipeline of experimental medicines.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of ...